Abstract

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalTrends in Biochemical Sciences
Volume32
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Proprotein Convertases
Molecular biology
LDL Lipoproteins
Metabolism
Molecular Biology
Coronary Disease
Plasmas
Mutation
LDL Receptors
Serine Proteases
Hypercholesterolemia
Liver
Peptide Hydrolases
Proprotein Convertase 9

ASJC Scopus subject areas

  • Biochemistry

Cite this

Molecular biology of PCSK9 : its role in LDL metabolism. / Horton, Jay D.; Cohen, Jonathan C.; Hobbs, Helen H.

In: Trends in Biochemical Sciences, Vol. 32, No. 2, 02.2007, p. 71-77.

Research output: Contribution to journalArticle

@article{8010510991f4418ea427c16eb379d4df,
title = "Molecular biology of PCSK9: its role in LDL metabolism",
abstract = "Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.",
author = "Horton, {Jay D.} and Cohen, {Jonathan C.} and Hobbs, {Helen H.}",
year = "2007",
month = "2",
doi = "10.1016/j.tibs.2006.12.008",
language = "English (US)",
volume = "32",
pages = "71--77",
journal = "Trends in Biochemical Sciences",
issn = "0376-5067",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Molecular biology of PCSK9

T2 - its role in LDL metabolism

AU - Horton, Jay D.

AU - Cohen, Jonathan C.

AU - Hobbs, Helen H.

PY - 2007/2

Y1 - 2007/2

N2 - Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

AB - Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

UR - http://www.scopus.com/inward/record.url?scp=33846679386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846679386&partnerID=8YFLogxK

U2 - 10.1016/j.tibs.2006.12.008

DO - 10.1016/j.tibs.2006.12.008

M3 - Article

VL - 32

SP - 71

EP - 77

JO - Trends in Biochemical Sciences

JF - Trends in Biochemical Sciences

SN - 0376-5067

IS - 2

ER -